Comparative Pharmacology
Head-to-head clinical analysis: NALOXONE HYDROCHLORIDE AUTOINJECTOR versus REVEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NALOXONE HYDROCHLORIDE AUTOINJECTOR versus REVEX.
NALOXONE HYDROCHLORIDE (AUTOINJECTOR) vs REVEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at mu, kappa, and delta opioid receptors, reversing opioid-induced respiratory depression and analgesia.
Nalmefene is an opioid antagonist that competitively binds to mu, delta, and kappa opioid receptors, reversing or preventing opioid effects.
Initial: 0.4 mg or 2 mg intramuscularly (IM) or subcutaneously (SC); may repeat every 2-3 minutes as needed. For autoinjector: 2 mg single dose, administer IM or SC into anterolateral thigh; may repeat every 2-3 minutes with a new device if no response. Max total dose: 10 mg.
0.5 mg to 1 mg intravenous, intramuscular, or subcutaneous, repeated every 2 to 5 minutes as needed, up to a maximum of 2 mg total dose per episode.
None Documented
None Documented
Terminal elimination half-life approximately 1 to 1.5 hours in adults. In neonates, half-life is prolonged (about 3 hours). Clinical context: due to short half-life, repeated doses or continuous infusion may be needed for opioid overdose with long-acting opioids.
Terminal elimination half-life: 2.4-4.2 hours in adults; prolonged in renal impairment (up to 50 hours).
Primarily hepatic metabolism (glucuronidation) followed by renal excretion of metabolites. Less than 1% excreted unchanged in urine. Fecal excretion minimal (<5%).
Renal: 60% as unchanged drug and metabolites; fecal: 40% via biliary elimination.
Category A/B
Category C
Opioid Antagonist
Opioid Antagonist